Clostridium difficile infection: an Australian clinical perspective
Grant A Jenkin
+ Author Affiliations
- Author Affiliations
Monash Infectious Diseases, Monash Medical Centre, 246 Clayton Road, Clayton, Vic. 3168, Australia
Department of Microbiology, Monash University, Clayton, Vic. 3800, Australia
Tel: +61 3 9594 4564
Fax: +61 3 9594 4533
Email: Grant.Jenkin@monash.edu
Microbiology Australia 36(3) 106-108 https://doi.org/10.1071/MA15037
Published: 12 August 2015
Abstract
The scale of the problem now posed by Clostridium difficile infection (CDI) is becoming frighteningly clear. Since 2001, a dramatic increase in the incidence and severity of CDI has occurred, particularly, in North America, the United Kingdom and Europe, associated with the emergence of a fluoroquinolone-resistant clone known as restriction endonuclease type BI, pulsed field type NAP1 or PCR ribotype 027 (RT027) Clostridium difficile (CD)1–3. CD is now the most commonly identified nosocomial pathogen in the USA4–6 and in 2011 there were approximately 450 000 incident cases of CDI in the USA and 29 300 deaths at day 30 post diagnosis6. Using an estimated attributable mortality rate of 50%, approximately 15 000 deaths due to CDI occurred in the USA in 2011.
References
[1] McDonald, L.C. et al. (2005) An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353, 2433–2441.| An epidemic, toxin gene-variant strain of Clostridium difficile.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2MXhtlShurvP&md5=2187acc1eb45b7b5617d8cc278d2c8a8CAS | 16322603PubMed |
[2] Loo, V.G. et al. (2005) A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353, 2442–2449.
| A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2MXhtlShurvK&md5=6788094548960b8b94f8aa6651317942CAS | 16322602PubMed |
[3] Kuijper, E.J. et al. (2006) Emergence of Clostridium difficile-associated disease in North America and Europe. Clin. Microbiol. Infect. 12, 2–18.
| Emergence of Clostridium difficile-associated disease in North America and Europe.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD28XhtFyhsLbN&md5=f78566ade542b5b6f707f46b3b1209bfCAS | 16965399PubMed |
[4] Magill, S.S. et al. (2014) Multistate point-prevalence survey of health care-associated infections. N. Engl. J. Med. 370, 1198–1208.
| Multistate point-prevalence survey of health care-associated infections.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXlvVCitLo%3D&md5=d2b61cb46b06949dd0b1b882a52b0d49CAS | 24670166PubMed |
[5] Leffler, D.A. and Lamont, J.T. (2015) Clostridium difficile infection. N. Engl. J. Med. 372, 1539–1548.
| Clostridium difficile infection.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2MXotFGls78%3D&md5=03ef346f9f7d64a5348abfbae5cfca19CAS | 25875259PubMed |
[6] Lessa, F.C. et al. (2015) Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 372, 825–834.
| Burden of Clostridium difficile infection in the United States.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2MXkt1Wqtb8%3D&md5=7938070fd46e57845cdc28c6cb4a2eb3CAS | 25714160PubMed |
[7] Slimings, C. et al. (2014) Increasing incidence of Clostridium difficile infection, Australia, 2011–2012. Med. J. Aust. 200, 272–276.
| Increasing incidence of Clostridium difficile infection, Australia, 2011–2012.Crossref | GoogleScholarGoogle Scholar | 24641152PubMed |
[8] See, I. et al. (2014) NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin. Infect. Dis. 58, 1394–1400.
| NAP1 strain type predicts outcomes from Clostridium difficile infection.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXnt1CntL4%3D&md5=4ce5f851dc4318325dd1db6d2989a18cCAS | 24604900PubMed |
[9] Petrella, L.A. et al. (2012) Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin. Infect. Dis. 55, 351–357.
| Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhtVeju77I&md5=4bcf215519332210f50a7667bb65ee60CAS | 22523271PubMed |
[10] Goorhuis, A. et al. (2008) Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin. Infect. Dis. 47, 1162–1170.
| Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1cXhtlGitb%2FF&md5=fa99770377d6557de89192e2bc2643a5CAS | 18808358PubMed |
[11] Wilcox, M.H. et al. (2012) Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin. Infect. Dis. 55, 1056–1063.
| Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC38jpt1SitA%3D%3D&md5=f4817832d51b4faab9e94a038b538d21CAS | 22784871PubMed |
[12] Riley, T.V. (2006) Epidemic Clostridium difficile. Med. J. Aust. 185, 133–134.
| 16893351PubMed |
[13] Riley, T.V. et al. (2009) First Australian isolation of epidemic Clostridium difficile PCR ribotype 027. Med. J. Aust. 190, 706–708.
| 19527210PubMed |
[14] Richards, M. et al. (2011) Severe infection with Clostridium difficile PCR ribotype 027 acquired in Melbourne, Australia. Med. J. Aust. 194, 369–371.
| 21470090PubMed |
[15] Australian Commission on Safety and Quality in Health Care (2015) Consultation on surveillance and monitoring of Clostridium difficile infection in Australia: discussion paper. ACSQHC, Sydney. http://www.safetyandquality.gov.au/our-work/healthcare-associated-infection/consultation-on-clostridium-difficile/ (accessed 9 June 2015).
[16] Foster, N.F. et al. (2014) Epidemiology of Clostridium difficile infection in two tertiary-care hospitals in Perth, Western Australia: a cross-sectional study. New Microbes New Infect. 2, 64–71.
| Epidemiology of Clostridium difficile infection in two tertiary-care hospitals in Perth, Western Australia: a cross-sectional study.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC2M3ksVGisg%3D%3D&md5=f2dd25531767384fd0236e889c38294fCAS | 25356346PubMed |
[17] Carter, G.P. et al. (2011) The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog. 7, e1002317.
| The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3MXhsVWqsrfJ&md5=f455541cf092215dd118d89427469dd6CAS | 22022270PubMed |
[18] Lim, S.K. et al. (2014) Emergence of a ribotype 244 strain of Clostridium difficile associated with severe disease and related to the epidemic ribotype 027 strain. Clin. Infect. Dis. 58, 1723–1730.
| Emergence of a ribotype 244 strain of Clostridium difficile associated with severe disease and related to the epidemic ribotype 027 strain.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXptVCgt7w%3D&md5=c819c9e6b5c95b08d0c1452d79cc5a5fCAS | 24704722PubMed |
[19] De Almeida, M.N. et al. (2013) Severe Clostridium difficile infection in New Zealand associated with an emerging strain, PCR-ribotype 244. N. Z. Med. J. 126, 9–14.
| 24126745PubMed |
[20] Eyre, D.W. et al. (2015) Emergence and spread of predominantly community-onset Clostridium difficile PCR ribotype 244 infection in Australia, 2010 to 2012. Euro Surveill. 20, 21059.
| 1:STN:280:DC%2BC2MnlvF2qtw%3D%3D&md5=a26b3727b879c8a6a1b642de28bf0032CAS | 25788254PubMed |
[21] He, M. et al. (2013) Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat. Genet. 45, 109–113.
| Emergence and global spread of epidemic healthcare-associated Clostridium difficile.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38Xhsl2lu7jE&md5=e19a32943aed675a0b4d802617f233c8CAS | 23222960PubMed |
[22] Louie, T.J. et al. (2011) Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364, 422–431.
| Fidaxomicin versus vancomycin for Clostridium difficile infection.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3MXhsFGhsLo%3D&md5=10eb2c5d83036226d7029310ef5c3a25CAS | 21288078PubMed |
[23] Wilcox, M. et al. (2013) Updated guidance on the management and treatment of Clostridium difficile infection. https://www.gov.uk/government/publications/clostridium-difficile-infection-guidance-on-management-and-treatment (accessed 9 June 2015)
[24] Debast, S.B. et al. (2014) European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin. Microbiol. Infect. 20, 1–26.
| European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXht1emur0%3D&md5=79716424fc86935fc88d38176effa19eCAS | 24118601PubMed |
[25] Jarrad, A.M. et al. (2015) Clostridium difficile drug pipeline: challenges in discovery and development of new agents. J. Med. Chem. 58, 5164–5185.
| Clostridium difficile drug pipeline: challenges in discovery and development of new agents.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2MXktFanur4%3D&md5=321170762cbafe462ef38fed03a10fc2CAS | 25760275PubMed |
[26] van Nood, E. et al. (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407–415.
| Duodenal infusion of donor feces for recurrent Clostridium difficile.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXitVelsbs%3D&md5=148fcb2e538e42f03185c046a044e287CAS | 23323867PubMed |
[27] Lawley, T.D. et al. (2012) Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog. 8, e1002995.
| Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38Xhs1OisLbO&md5=1eaeb2b5d7218c3c87a0b88344fb31f5CAS | 23133377PubMed |
[28] Gerding, D.N. et al. (2015) Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA 313, 1719–1727.
| Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial.Crossref | GoogleScholarGoogle Scholar | 25942722PubMed |
[29] Buffie, C.G. et al. (2015) Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517, 205–208.
| Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXhvVemtrvE&md5=af1044b700817647e9be90bb723446feCAS | 25337874PubMed |
[30] Lowy, I. et al. (2010) Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362, 197–205.
| Treatment with monoclonal antibodies against Clostridium difficile toxins.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3cXosFShtw%3D%3D&md5=f9c4b20bdea27ef940ac293008ff79caCAS | 20089970PubMed |
[31] A study of MK-3415 MK-6072, and MK-3415A in participants receiving antibiotic therapy for Clostridium difficile infection (MK-3415A-001) (MODIFY I). https://clinicaltrials.gov/ct2/show/NCT01241552 (accessed 9 June 2015).
[32] Study of a candidate Clostridium difficile toxoid vaccine in subjects at risk for C. difficile infection. https://clinicaltrials.gov/ct2/show/NCT01887912 (accessed 9 June 2015).
